Synapse - Exploring the clinical significance of serous tubal intraepithelial carcinoma associated with advanced high-grade serous ovarian cancer: A Memorial Sloan Kettering Team Ovary study

Exploring the clinical significance of serous tubal intraepithelial carcinoma associated with advanced high-grade serous ovarian cancer: A Memorial Sloan Kettering Team Ovary study Journal Article

Authors:	Boerner, T.; Walch, H. S.; Nguyen, B.; Iasonos, A.; Zhou, Q. C.; Schultz, N.; Chui, M. H.; Grisham, R. N.; Tew, W. P.; O'Cearbhaill, R. E.; Aghajanian, C.; Zivanovic, O.; Abu-Rustum, N. R.; Gardner, G. J.; Sonoda, Y.; Chi, D. S.; Long Roche, K.
Article Title:	Exploring the clinical significance of serous tubal intraepithelial carcinoma associated with advanced high-grade serous ovarian cancer: A Memorial Sloan Kettering Team Ovary study
Abstract:	Objective: To evaluate the clinical significance and genomic associations of concurrent serous tubal intraepithelial carcinoma (STIC) with high-grade serous carcinoma (HGSC) of the ovary in women undergoing primary debulking surgery (PDS). Methods: All patients who underwent PDS for HGSC between 01/2015 and 12/2018 were captured in a prospectively maintained institutional database. Patients were categorized based on the presence or absence of concurrent STIC noted on final pathology. Demographic, perioperative, and outcomes data were collected, and groups were compared using standard statistical tests. Progression-free survival (PFS) and overall survival (OS) were evaluated using the Kaplan-Meier method. For comparison of differences in somatic alterations between the two cohorts, specimens were sequenced using MSK-IMPACT. Results: Of 306 eligible patients, 87 (28%) had a concurrent STIC lesion (+STIC) and 219 (72%) did not (no-STIC). Demographics and clinicopathological factors were similar between the two cohorts, except for a significantly higher median preoperative CA-125 level in the no-STIC group (423 U/mL vs. 321 U/mL; p=0.029). There were no significant differences in median PFS (22.7 months [95%CI: 18.9-28.4] vs. 27.7 months [95%CI: 25.5-30.5]; p=0.126) and 3- year OS rate (81% [95%CI: 70-88%] vs. 85% [95%CI: 78-90%]; p=0.392) between +STIC and no-STIC patients, respectively. Targeted DNA-sequencing via MSK-IMPACT showed a similar distribution of driver mutations or structural genetic alterations, and affected genetic signaling pathways were similar between the cohorts. Conclusions: There were no identifiable clinical and genetic differences in patients with HGSC and concurrent STIC. These data suggest a comparable, if not identical, disease process. © 2020 Elsevier Inc.
Keywords:	primary debulking surgery; serous tubal intraepithelial carcinoma; msk-impact; high-grade serous ovarian cancer; mutation profiling
Journal Title:	Gynecologic Oncology
Volume:	160
Issue:	3
ISSN:	0090-8258
Publisher:	Elsevier Inc.
Date Published:	2021-03-01
Start Page:	696
End Page:	703
Language:	English
DOI:	10.1016/j.ygyno.2020.12.022
PUBMED:	33386131
PROVIDER:	scopus
PMCID:	PMC7902425
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85098562643&doi=10.1016%2fj.ygyno.2020.12.022&partnerID=40&md5=59cb182ece277a3b6bd9f97289b0f68b
Notes:	Article -- Export Date: 1 April 2021 -- Source: Scopus